Skip to content

Journal of Psychoactive Drugs

ISSN 0279-1072, 2159-9777

419 papers in the library · 13,118 citations · publishing 1976-2026

Papers

Sort Most recent Most cited

Psychedelic-Assisted Group Therapy: A Systematic Review

Journal of Psychoactive Drugs March 15, 2019 Alexander Trope, B. Anderson, Andrew R. Hooker et al. 113 citations

Contemporary research with classic psychedelic drugs (e.g., lysergic acid diethylamide (LSD) and psilocybin) is indebted to the twentieth-century researchers and clinicians who generated valuable clinical knowledge of these substances through experimentation. Several recent reviews that highlight the contributions of this early literature have focused on psychedelic-assisted individual...

The Past and Future of Psychedelic Science: An Introduction to This Issue

Journal of Psychoactive Drugs March 15, 2019 Lisa Jerome, Brad Burge, Richard Doblin et al. 87 citations

Psychedelic plants and fungi have been used in indigenous medicinal traditions for millennia. Modern psychedelic research began when Albert Hofmann first synthesized lysergic acid diethylamide (LSD-25) in 1938. Five years later, became the first person to ingest LSD. Hofmann was unaware of the significance of his actions, and the effects they would set in motion. After a burgeoning period of...

Effects of the Psychedelic Amphetamine MDA (3,4-Methylenedioxyamphetamine) in Healthy Volunteers

Journal of Psychoactive Drugs March 15, 2019 Matthew J. Baggott, Kathleen J. Garrison, Jeremy Coyle et al. 20 citations

Entactogens such as 3,4-Methylenedioxymethamphetamine (MDMA, "molly", "ecstasy") appear to have unusual, potentially therapeutic, emotional effects. Understanding their mechanisms can benefit from clinical experiments with related drugs. Yet the first known drug with such properties, 3,4-Methylenedioxyamphetamine (MDA), remains poorly studied and its pharmacokinetics in humans are unknown. We...

Embracing Neurodiversity in Psychedelic Science: A Mixed-Methods Inquiry into the MDMA Experiences of Autistic Adults

Journal of Psychoactive Drugs March 15, 2019 A. Danforth 14 citations

ABSTRACT This exploratory inquiry analyzed subjective experiences autistic adults reported after they took the drug 3,4-methylenedioxymethamphetamine (MDMA), also known as ecstasy, in nonclinical settings. Using a secure, globally available website, this study collected data from participants in 13 countries who were experienced with MDMA (n = 100). A subset of survey respondents (n = 24) were...

Perceived Benefits of MDMA-Assisted Psychotherapy beyond Symptom Reduction: Qualitative Follow-Up Study of a Clinical Trial for Individuals with Treatment-Resistant PTSD

Journal of Psychoactive Drugs March 8, 2019 William P. Barone, Jerome Beck, Michiko Mitsunaga-Whitten et al. 63 citations

We present select findings from a long-term follow-up qualitative study of MDMA-assisted psychotherapy for veterans, firefighters, and police officers suffering from chronic, treatment-resistant PTSD. Semi-structured qualitative interviews were conducted at participants' one-year follow-up after a recently completed phase 2 clinical trial. Available interviews from 19 of 24 participants were...

DOI: 10.1080/02791072.2019.1580805 (opens in new tab) MDMA Thematic analysis Qualitative research Interpretative phenomenological analysis +4

Beyond LSD: A Broader Psychedelic Zeitgeist during the Early to Mid-20thCentury

Journal of Psychoactive Drugs March 6, 2019 Jacob S. Aday, Emily K. Bloesch, Christopher C. Davoli 19 citations

During the 1950s and 1960s, there was a tremendous surge in research into the effects of psychedelic drugs. When discussing this period of research, the discovery of the psychoactive properties of LSD in 1943 is often presented as the main, and sometimes only, driving force of the boom in research. This "Great Person," or "Great Chemical," historiographical lens fails to acknowledge other...

Comparing Mental Health across Distinct Groups of Users of Psychedelics, MDMA, Psychostimulants, and Cannabis

Journal of Psychoactive Drugs March 6, 2019 Ansgar Rougemont-Bücking, Henrik Jungaberle, Milan Scheidegger et al. 6 citations

Differences in mental health (MH) of users of distinct psychoactive substances have been shown. Both substance use (SU) and MH in users are influenced by stressful life events. This study compared MH parameters in distinct groups of substance users and evaluated the impact of stress factors on these outcomes. Data stem from the longitudinal Swiss Cohort Study on Substance Use Risk Factors...

Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being

Journal of Psychoactive Drugs February 26, 2019 Natasha L. Mason, Elisabeth Mischler, Malin V. Uthaug et al. 176 citations

Creative thinking and empathy are crucial for everyday interactions and subjective well-being. This is emphasized by studies showing a reduction in these skills in populations where social interaction and subjective well-being are significantly compromised (e.g., depression). Anecdotal reports and recent studies suggest that a single administration of psilocybin can enhance such processes and...

DOI: 10.1080/02791072.2019.1580804 (opens in new tab) Psilocybin Empathy Clinical psychology Developmental psychology +1

Dorsolateral Prefrontal Cortex Impairment in Methoxetamine-Induced Psychosis: An 18F-FDG PET/CT Case Study

Journal of Psychoactive Drugs February 9, 2019 Lorenzo Moccia, A. Tofani, Marianna Mazza et al. 10 citations

Novel psychoactive substances (NPSs) have currently become a major public health concern because of relatively easy accessibility to these compounds and difficulty in identifying them with routine laboratory techniques. Here, we report the 18F-fluorodeoxyglucose positron emission tomography/computerized tomography (18F-FDG PET/CT) case study of a 23-year-old man who developed a...

DOI: 10.1080/02791072.2019.1578444 (opens in new tab) Dorsolateral prefrontal cortex Positron emission tomography Verbal fluency test Working memory +6

Ayahuasca and Public Health: Health Status, Psychosocial Well-Being, Lifestyle, and Coping Strategies in a Large Sample of Ritual Ayahuasca Users

Journal of Psychoactive Drugs February 7, 2019 Genís Ona, Maja Kohek, Tomàs Massaguer et al. 76 citations

Assessing the health status of ayahuasca users has been challenging due to the limitations involved in randomized clinical trials and psychometric approaches. The main objective of this study is the implementation of an approach based on public health indicators. We developed a self-administered questionnaire that was administered to long-term ayahuasca users around Spain. The questionnaire was...

DOI: 10.1080/02791072.2019.1567961 (opens in new tab) Ayahuasca Psychosocial Public health Medical prescription +1

A First-in-Man Study with 4-Fluoroamphetamine Demonstrates it Produces a Mild Psychedelic State

Journal of Psychoactive Drugs January 24, 2019 Kim P. C. Kuypers, E. B. de Sousa Fernandes Perna, Eef L. Theunissen et al. 13 citations

The phenethylamine 4-fluoroamphetamine (4-FA) is a so-called novel psychoactive substance with a chemical structure resembling that of amphetamine and MDMA. Since 4-FA users report their subjective experience ranges between the effects induced by amphetamine and MDMA, and it is known that both substances can produce an altered state of consciousness, this study tests whether 4-FA induces a...

Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration.

Journal of Psychoactive Drugs 2019 James Fadiman, Sophia Korb 122 citations

Albert Hoffman suggested that low doses of LSD might be an appropriate alternative to Ritalin. Following this possibility, a systematic exploration of the effects of "microdoses," comprising hundreds of lengthy descriptive reports, was undertaken. Based on these reports, using a psychedelic in the microdose range (10 micrograms) every three days was determined to be safe across a wide variety...

Combining Cognitive-Behavioral Conjoint Therapy for PTSD with 3,4-Methylenedioxymethamphetamine (MDMA): A Case Example.

Journal of Psychoactive Drugs 2019 Anne C Wagner, Michael C Mithoefer, Ann T Mithoefer et al. 92 citations

Treatments for posttraumatic stress disorder (PTSD) have evolved significantly in the past 35 years. From what was historically viewed as a pervasive, intractable condition have emerged multiple evidence-based intervention options. These treatments, predominantly cognitive behavioral in orientation, provide significant symptom improvement in 50-60% of recipients. The treatment of PTSD with...

Short-Term Treatment Effects of a Substance Use Disorder Therapy Involving Traditional Amazonian Medicine.

Journal of Psychoactive Drugs 2019 Ilana Berlowitz, Heinrich Walt, Christian Ghasarian et al. 70 citations

Chronic illness management today commonly involves alternative medicines. Substance use disorder (SUD), as a chronic psychosomatic illness, might benefit from a similar approach. The accredited Takiwasi Center offers such an SUD treatment program involving Amazonian medicine combined with psychotherapy. The current study assessed this integrative program's short-term therapeutic effects. We...

Ibogaine and Subjective Experience: Transformative States and Psychopharmacotherapy in the Treatment of Opioid Use Disorder.

Journal of Psychoactive Drugs 2019 Thomas K Brown, Geoff Noller, Julie O Denenberg 48 citations

This article examines the therapeutic potential of ibogaine, a powerful oneiric alkaloid derived from Tabernanthe iboga, through exploring the subjective experiences of 44 participants from two observational treatment studies for opioid use disorder. Following treatment with ibogaine HCl, the participants (Mexico, n = 30; New Zealand, n = 14) completed the States of Consciousness Questionnaire...

DOI: 10.1080/02791072.2019.1598603 (opens in new tab) Full text (opens in new tab) Hallucinogen Opioids Ibogaine therapy ibogaine Complete mystical experiences +1

Psychedelics and Dying Care: A Historical Look at the Relationship between Psychedelics and Palliative Care.

Journal of Psychoactive Drugs 2019 Erika Dyck 16 citations

This article examines the historical relationship between psychedelics and palliative care. Historians have contributed to a growing field of studies about how psychedelics have been used in the past, but much of that scholarship focused on interrogating questions of legitimacy or proving that psychedelics had therapeutic potential. Palliative care had not yet developed as medical...

DOI: 10.1080/02791072.2019.1581308 (opens in new tab) Full text (opens in new tab) Death and dying Medical humanities Palliative care Psychedelics +1

On Addiction, Complexity, and Freedom: Toward a Liberation-Focused Addiction Treatment.

Journal of Psychoactive Drugs 2019 Scott Kellogg 4 citations

This article outlines a liberation-focused model of addiction treatment. Drawing on the Latin root word "addictus", addiction is seen as slavery and freedom, rather than the cessation of drug and alcohol use, is proposed as a viable, alternative treatment goal. Freedom is defined as: (1) the capacity to create a life of social and internal complexity and multiplicity; (2) the ability to make...

DOI: 10.1080/02791072.2018.1564157 (opens in new tab) Full text (opens in new tab) Ibogaine Addiction psychotherapy Addiction treatment Harm reduction +3

The Role of the Journal of Psychedelic Drugs in the Evolution of Psychedelic Medicine.

Journal of Psychoactive Drugs 2019 David E Smith 3 citations

A review of the primary role that this journal (and by extension, Dr. David Smith) has played in bearing witness to the second wave of psychedelic research as our modern-day culture embraces the current third wave of the psychedelic revival, exploring through research its therapeutic uses.

Effect of Ritualistic Consumption of Ayahuasca on Hepatic Function in Chronic Users

Journal of Psychoactive Drugs December 22, 2018 Sueli Moreira Mello, Paula Christiane Soubhia, Gabriela de Oliveira Silveira et al. 15 citations

Ayahuasca is a beverage obtained from decoctions of the liana Banisteriopsis caapi plus the shrub Psychotria viridis. This beverage contains a combination of monoamine oxidase inhibitors (harmine, harmaline, and tetrahydroharmine) and N,N-dimethyltryptamine, the main substance responsible for its visionary effect. The ritualistic use of ayahuasca is becoming a global phenomenon. Most members of...

DOI: 10.1080/02791072.2018.1557355 (opens in new tab) Ayahuasca Decoction Context archaeology Harmaline +3

Therapeutic Potential Ascribed to Ayahuasca by Users in the Czech Republic

Journal of Psychoactive Drugs August 30, 2018 Miroslav Horák, Lea Hasíková, Nahanga Verter 16 citations

This article focuses on the therapeutic potential ascribed to ayahuasca by users in the Czech Republic. Following an online survey, the fieldwork among users of ayahuasca was carried out from November 2015 to December 2016. The research sample consisted of 46 persons (23 women and 23 men), who took part at least once in some type of ayahuasca ritual and/or were the facilitators of the ayahuasca...

A Gratuitous Grace: The Influence of Religious Set and Intent on the Psychedelic Experience

Journal of Psychoactive Drugs August 8, 2018 Logan Neitzke-Spruill, Carol Glasser 27 citations

Psychedelic drugs, or entheogens, have been used for religious purposes among various cultures for thousands of years. Recently, these substances have caught the attention of Westerners for many reasons, including their propensity to induce mystical experiences. This study examined the relationship between religion and having mystical experiences. A total of 119 participants were drawn from...

Is Ayahuasca an Option for the Treatment of Crack Cocaine Dependence?

Journal of Psychoactive Drugs April 2, 2018 Joselaine Ida Da Cruz, Solange Aparecida Nappo 35 citations

The low efficacy of crack cocaine addiction treatment available in Brazil has led Brazilian users to find alternatives to reduce drug consumption or even to reach abstinence. One of them is the use of entheogenic substances, like ayahuasca, an infusion obtained from two native plant species from the Amazon. The present report aimed to understand how crack cocaine users recover from drug...

Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine.

Journal of Psychoactive Drugs 2018 Benjamin Malcolm, Martin Polanco, Joseph P Barsuglia 64 citations

Opioid use disorder (OUD) is currently an epidemic in the United States (US) and ibogaine is reported to have the ability to interrupt opioid addiction by simultaneously mitigating withdrawal and craving symptoms. This study examined opioid withdrawal and drug craving scores in 50 participants with OUD undergoing a week-long detoxification treatment protocol with ibogaine. The Addiction...

DOI: 10.1080/02791072.2018.1447175 (opens in new tab) Full text (opens in new tab) Opiate Ibogaine treatment ibogaine Therapy Medication +8

A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification.

Journal of Psychoactive Drugs 2018 Alan K. Davis, Elise Renn, Austin-Marley Windham-Herman et al. 34 citations

We examined persisting effects, self-perceived challenges, and potential benefits associated with positive outcomes following ibogaine detoxification using data collected as part of a larger online retrospective study of 73 patients who received treatment for chronic opioid use in Mexico between 2012 and 2015. A mixed-methods design was used comparing treatment responders versus non-responders,...

The Domino Effect: Ed Domino's early studies of Psychoactive Drugs.

Journal of Psychoactive Drugs 2018 Nicholas Denomme

University of Michigan Pharmacology Professor Ed Domino is an expert in the field of neuropsychopharmacology. For over six decades, Dr. Domino has made many contributions to our understanding of psychoactive drugs, but is most well-known for his role in the development of ketamine anesthesia. This article covers the story behind this discovery, along with many other fascinating personal and...